What's next for Alzheimer's disease research?

Alia Paavola - Print  | 

Last week, Biogen and Eisai halted two phase 3 clinical trials of its once-promising Alzheimer's disease drug, leading many people to ask — what now?

Here is a breakdown of how Alzheimer's disease research is progressing despite the latest setback, according to The Wall Street Journal.

More articles on pharmacy:
10 hospitals seeking pharmacy leadership
Patent protection clause is latest stumbling block for revised NAFTA
Dr. Reddy's legal win expected to lower cost of opioid addiction treatment

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.